German Covid-19 vaccine maker to raise $200m
GlobalCapital, is part of the Delinian Group, DELINIAN (GLOBALCAPITAL) LIMITED, 4 Bouverie Street, London, EC4Y 8AX, Registered in England & Wales, Company number 15236213
Copyright © DELINIAN (GLOBALCAPITAL) LIMITED and its affiliated companies 2024

Accessibility | Terms of Use | Privacy Policy | Modern Slavery Statement
Cookies Settings
EquityABBs-Block Trades

German Covid-19 vaccine maker to raise $200m

Victoria Thiele
February 07, 2023 03:57 PM
Illustration picture shows the start of the final test phase of the CureVac coronavirus vaccine, developed by the German pharmaceuticals company CureV

CureVac launched a capital increase following encouraging research results

Unlock this article.

The content you are trying to view is exclusive to our subscribers.

To unlock this article:

Request a Free Trial or Login

Topics

ABBs-Block TradesGermanyUnited StatesGoldman SachsJefferies LLC
VT
Victoria Thiele
Senior Reporter - CLOs
Contact
Gift this article